ArticleMedical mycology case reports2019
Article in Medical mycology case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 43 citations in OpenAlex.
- Clinical and Microbiological Characteristics of Sterile-Site Saccharomyces cerevisiae Infections in a Tertiary-Care Centre.Mycopathologia · 2026Article
- Typing of clinical and reference strains of Saccharomyces cerevisiae using pulsed-field gel electrophoresis and MALDI-TOF MS.Scientific reports · 2025Article
- Exploring the dark side of probiotics to pursue light: Intrinsic and extrinsic risks to be opportunistic pathogens.Current research in food science · 2025Review
- Rare multi-fungal sepsis: a case of triple-impact immunoparalysis.Folia microbiologica · 2024Article
- Accounting for the health risk of probiotics.Heliyon · 2024Review
- Increased Incidence and Risk of Septicemia and Urinary Tract Infection AfterOpen forum infectious diseases · 2023Article
- A case of bloodstream co-infection of Saccharomyces cerevisiae and Candida glabrata while using micafungin.BMC infectious diseases · 2023Article
- Concurrent and Subsequent Co-Infections ofMicroorganisms · 2022Review
- Probiotics: Should All Patients Take Them?Microorganisms · 2021Review
- Virulence Factors and in-Host Selection on Phenotypes in Infectious Probiotic Yeast Isolates (Journal of fungi (Basel, Switzerland) · 2021Article
- Fungemia and Other Fungal Infections Associated with Use of Saccharomyces boulardii Probiotic Supplements.Emerging infectious diseases · 2021Article
- The Role of Fatty Acid Metabolites in Vaginal Health and Disease: Application to Candidiasis.Frontiers in microbiology · 2021Review
- Safety of Probiotics: Functional Fruit Beverages and Nutraceuticals.Foods (Basel, Switzerland) · 2020Review
- A Brief Review of Nutraceutical Ingredients in Gastrointestinal Disorders: Evidence and Suggestions.International journal of molecular sciences · 2020Review
- Update of the list of QPS-recommended biological agents intentionally added to food or feed as notified to EFSA 11: suitability of taxonomic units notified to EFSA until September 2019.EFSA journal. European Food Safety Authority · 2020Article
- Rising Into Relevance: A Rare Case ofJournal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Saccharomyces cerevisiae has recently been used as an ingredient in probiotic supplements. Invasive Saccharomyces infection have been documented, and multiple predisposing risk factors have been identified including critical illness, ICU admission, antibiotics use, central venous catheters, probiotics use, and immunosuppression. We report a case of a 74-year-old man admitted for acute cholangitis taking a probiotic supplement containing the subtype Saccharomyces boulardii. He later developed S. cerevisiae fungemia that was successfully treated with Micafungin and Fluconazole.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.